KR910011897A - 말라리아 백신 - Google Patents

말라리아 백신 Download PDF

Info

Publication number
KR910011897A
KR910011897A KR1019900020293A KR900020293A KR910011897A KR 910011897 A KR910011897 A KR 910011897A KR 1019900020293 A KR1019900020293 A KR 1019900020293A KR 900020293 A KR900020293 A KR 900020293A KR 910011897 A KR910011897 A KR 910011897A
Authority
KR
South Korea
Prior art keywords
asn
lys
asp
pro
gly
Prior art date
Application number
KR1019900020293A
Other languages
English (en)
Inventor
스튜어트 그로스 미첼
매튜 고든 다니엘
리챠드 홀링데일 마이클
Original Assignee
원본미기재
스미스클라인 비참 코포레이숀
바이오메디칼 리써취 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 스미스클라인 비참 코포레이숀, 바이오메디칼 리써취 인스티튜트 filed Critical 원본미기재
Publication of KR910011897A publication Critical patent/KR910011897A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

말라리아 백신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 플라스모듐(Plasmodium)표면 단백질의 첫번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자,플라스모듐(Plasmodium)표면 단백질의 두번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자 및 첫번째와 두번째 측면 영역사이에 있는 반복서열 도메인에서 유래된 반복되는 면역원성 결정인자의 일부를 함유하거나, 또는 이 반복되는 면역원성 결정인자는 함유하지 않으며, 상기 첫번째 측면 영역에서 유래된 면역원성 결정인자 중 적어도 하나가 다음의 아미노산 서열 :
    Gly-Asp-Asn-Gly-Arg-Glu-Gly-Lys; Glu-Lys-Leu-Arg-Lys-Pro-Lys; 또는 Leu-Lys-Gln-Pro-Gly-Asp-Gly-Asn; 에 의해 코팅되어 있음을 특징으로 하는 폴리펩티드 또는 그의 기능적 균등체.
  2. 플라스모듐(Plasmodium)표면 단백질의 첫번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자,플라스모듐(Plasmodium)표면 단백질의 두번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자 및 첫번째와 두번째 측면 영역사이에 있는 반복서열 도메인에서 유래된 반복되는 면역원성 결정인자의 일부를 함유하거나, 또는 이 반복되는 면역원성 결정인자는 함유하지 않으며, 상기 두번째 측면 영역에서 유래된 면역원성 결정인자 중 적어도 하나가 다음의 아미노산서열 : Pro-Asn-Asp-Pro-Asn-Arg-Asn-Val-Asp-Gln-Asn-Als; 또는 Asn-Lys-Pro-Lys-Asp-Glu-Leu-Asp; 에 의해 코팅되어 있음을 특징으로 하는 폴리펩티드 또는 그의 기능적 균등체.
  3. 플라스모듐(Plasmodium)표면 단백질의 첫번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자,플라스모듐(Plasmodium)표면 단백질의 두번째 측면 영역에서 유래된 하나 이상의 면역원성 결정인자 및 첫번째와 두번째 측면 영역 사이에 있는 반복서열 도메인에서 유래된 반복되는 면역원성 결정인자의 일부를 함유하거나, 또는 이 반복되는 면역원성 결정인자는 함유하지 않으며, 상기 첫번째 측면 영역에서 유래된 면역원성 결정인자 중 적어도 하나가 다음의 아미노산 서열 :
    Gly-Asp-Asn-Gly-Arg-Glu-Gly-Lys;Glu-Lys-Leu-Arg-Lys-Pro-Lys; 또는 Leu-Lys-Gln-Pro-Gly-Asp-Gly-Asn; 에 의해 코팅되어 있고, 상기 두번째 측면 영역에서 유래된 면역원성 결정인자중 적어도 하나가 다음의 아미노산 서열: Pro-Asn-Asp-Pro-Asn-Arg-Asn-Val-Asp-Gln-Asn-Ala; 또는Asn-Lys-Pro-Lys-Asp-Glu-Leu-Asp;에 의해 코팅되어 있음을 특징으로 하는 폴리펩티드 또는 그의 기능적 균등체.
  4. 플라스모듐(Plasmodium)표면 단백질의 반복서열 도메인에서 유래된 반복되는 면역원성 결정인자의 일부를 함유하거나, 또는 함유하지 않고, 다음의 아미노산 서열 : Gly-Asp-Asn-Gly-Arg-Glu-Gly-Lys; Glu-Lys-Leu-Arg-Lys-Pro-Lys; Leu-Lys-Gln-Pro-Gly-Asp-Gly-Asn;Pro-Asn-Asp-Pro-Asn-Arg-Asn-Val-Asp-Gln-Asn-Als; 또는 Asn-Lys-Pro-Lys-Asp-Glu-Leu-Asp; 에 의해 코팅되는 적어도 하나의 펩티드를 함유함을 특징으로 하는 폴리펩티드 또는 그의 기능적 균등체.
  5. 제1항 내지 4항중 어느 한항에 있어서, 하이브리드 폴리펩티드인 폴리펩티드.
  6. 제5항에 있어서, 펩티드를 담체 단백질에 화학적으로 융합시킨 산물인 폴리펩티드.
  7. 제6항에 있어서, 담체 단백질이 파상풍 톡소이드, 디프테리아 독소 또는 B형 콜레라 독소인 폴리펩티드.
  8. 제7항에 있어서, 화학적 융합이 커플링제인 글루타르 알데히드를 통하여 중개되는 폴리펩티드.
  9. 제7항에 있어서, 파상풍 톡소이드에의 융합이 펩티드의 N-말단에 있는 시스테인 잔기를 통하여 중개되는 폴리펩티드.
  10. 제7항에 있어서, 파상풍 톡소이드에의 융합이 펩티드의 N-말단에 있는 시스테인 잔기 및 C-말단에 있는 시스테인 잔기를 통하여 중개되는 폴리펩티드.
  11. 제10항에 있어서, 커플링제인 글루타르 알데히드를 통한 아미노산 서열 Cys-Pro-Asn-Asp-Pro-Asn-Arg-Asn-Val-Asp-Glu-Asn-Ala-Cys과 파상풍 톡소이드와의 결합 산물인 폴리펩티드.
  12. 제1항 내지 11항중 어느 한항의 폴리펩티드를 코딩하는 발현벡터.
  13. 면역방어학적 양의 제1항 내지 11항중 어느 한항의 폴리펩티드 및 제약학적으로 허용되는 담체를 함유함을 특징으로 하는플라스모듐(Plasmodium)종충에 의한 감염으로 부터 사람을 보호하기 위한 백신.
  14. 유효하고 무독성인 양의 제13항의 백신을플라스모듐(Plasmodium)종충에 의한 감염으로 부터 보호할 필요한 사람에게 투여함을 특징으로 하는,플라스모듐(Plasmodium)종충에 의한 감염으로 부터 보호할 필요가 있는 사람의 면역방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900020293A 1989-12-08 1990-12-08 말라리아 백신 KR910011897A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774689A 1989-12-08 1989-12-08
US07447746 1989-12-08

Publications (1)

Publication Number Publication Date
KR910011897A true KR910011897A (ko) 1991-08-07

Family

ID=23777585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900020293A KR910011897A (ko) 1989-12-08 1990-12-08 말라리아 백신

Country Status (18)

Country Link
EP (1) EP0432965A1 (ko)
JP (1) JPH0673097A (ko)
KR (1) KR910011897A (ko)
CN (1) CN1053814A (ko)
AU (1) AU634837B2 (ko)
CA (1) CA2031468A1 (ko)
FI (1) FI906051A (ko)
HU (1) HUT56882A (ko)
IE (1) IE904412A1 (ko)
IL (1) IL96579A0 (ko)
MA (1) MA22097A1 (ko)
MY (1) MY105313A (ko)
NO (1) NO905301L (ko)
NZ (1) NZ236357A (ko)
PL (1) PL288140A1 (ko)
PT (1) PT96132A (ko)
ZA (1) ZA909838B (ko)
ZW (1) ZW19090A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
KR950702635A (ko) * 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
AU7724894A (en) * 1993-09-10 1995-03-27 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
ES2371066T3 (es) * 2002-11-20 2011-12-27 Sanaria Inc. Vacuna para la prevención del paludismo.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
IT1196501B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Polipeptide utile per la preparazione di vaccini per la malaria e di kits diagnostici per la determinazione di affezioni malariche
WO1988005817A1 (en) * 1987-01-30 1988-08-11 Smith Kline - Rit S.A. Expression of the p. falciparum circumsporozoite protein by yeast
CA2015722A1 (en) * 1989-05-03 1990-11-03 Mitchell S. Gross Malaria vaccine

Also Published As

Publication number Publication date
NZ236357A (en) 1993-01-27
ZA909838B (en) 1992-05-27
PT96132A (pt) 1991-09-30
IE904412A1 (en) 1991-06-19
NO905301D0 (no) 1990-12-07
AU634837B2 (en) 1993-03-04
MA22097A1 (fr) 1991-12-31
ZW19090A1 (en) 1991-04-10
FI906051A0 (fi) 1990-12-07
IL96579A0 (en) 1991-09-16
CA2031468A1 (en) 1991-06-09
MY105313A (en) 1994-09-30
HU908128D0 (en) 1991-06-28
JPH0673097A (ja) 1994-03-15
FI906051A (fi) 1991-06-09
EP0432965A1 (en) 1991-06-19
NO905301L (no) 1991-06-10
CN1053814A (zh) 1991-08-14
HUT56882A (en) 1991-10-28
AU6777490A (en) 1991-06-13
PL288140A1 (en) 1991-10-21

Similar Documents

Publication Publication Date Title
CA2224724A1 (en) Subunit vaccine against flavivirus infection
EP0835315A4 (en) PIG RESPIRATORY DYSGENESIS SYNDROME VACCINE
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
WO1995012677A3 (en) Immunodominant human t-cell epitopes of hepatitis c virus
HK1032511A1 (en) Proteins encoded by polynucleic cids of porcine reproductive and respiratory syndrome virus (prrsv)
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
GB2255093A (en) Hiv-1 core protein fragments
KR910011897A (ko) 말라리아 백신
EP0467700A3 (en) Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties
ES2160601T3 (es) Vacunas de conjugado de polisacaridos de estreptococos del grupo b tipo ii y tipo v-proteina.
GR3029264T3 (en) Anti-feline immunodeficiency virus (fiv) vaccines.
WO1994010317A3 (en) Conjugate vaccine against group b streptococcus
ATE287957T1 (de) Peptide abgeleitet vom bindungs (g) protein des respiratorisches synzytialvirus
SG63621A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
GB2250994A (en) Peptide fragments of hiv
EP0762895A4 (en) SYNTHESIS VACCINE PROTECTING AGAINST HIV INFECTION
WO1993014206A3 (en) Synthetic peptides for a rubella vaccine
KR950700415A (ko) 말라리아 백신(improvements in or relating to malaria vaccine)
KR950701821A (ko) 피임 백신(contraceptive vaccine)
WO2002051865A3 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
ATE305941T1 (de) Impfstoff
CO4750675A1 (es) Vacuna de env-glucoproteina para la proteccion contra la infeccion con vlcth-i y vclth-ii
KR950701683A (ko) 클로스트리디움 퍼프린겐스 백신(Clostridium perfringens wvaccines)
UY25600A1 (es) Antígenos protectores contra la infección por echinococcus granulosus y vacunas que contienen dichos antígenos
KR970074790A (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid